research Effects of Testosterone+Finasteride on Bone After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Testosterone plus finasteride increases bone density in men with spinal cord injuries.
Search
for
Sort by
Research
450-480 / 1000+ results
research Nonablative Er:YAG Laser Treatment of Androgenetic Alopecia: A Clinical Observation
The laser treatment improved hair appearance and was safe and well-received by patients.
research Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study
The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
research Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
Baricitinib shows promise for treating alopecia areata with mild side effects.
research Efficacy of different doses of Platelet-Rich Plasma for Moderate Carpal Tunnel Syndrome:Study Protocol for a Prospective, Randomized, Controlled trail
The study aims to find the best PRP dose for treating moderate carpal tunnel syndrome.
research 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
research Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.
The treatment was not recommended due to limited effectiveness and significant side effects.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
research P111 : Low-Level light therapy in the treatment of androgenetic alopecia: A 24-week, randomized, double-blind, sham device-controlled multicenter trial
The Hair660™ light therapy device effectively and safely improves hair density in people with androgenetic alopecia.
research Step-down approach to concentration of intra-lesional triamcinolone acetonide in treatment of scalp patchy alopecia areata: insights from an open-label randomized trial
Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program
research Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer
Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.
research Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases
Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil
The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
research Objective and Subjective Assessments of the Response of Photobiomodulation Therapy Against Alopecia Areata
Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
research MP09-17 METHYLATION OF SRD5A2 IN THE BLOOD AS A NOVEL BIOMARKER TO PREDICT SENSITIVITY TO 5-ARI TREATMENT
SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
research Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
research American College of Clinical Pharmacology Twenty‐Second Annual Meeting November 1–3, 1993 Boston, Massachusetts
research News & Notes
Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
research Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.